Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations [Urologic Oncology]

Conclusion
Afatinib demonstrated significant activity in patients with platinum-refractory UC with HER2 or ERBB3 alterations. The potential contribution of ERBB3 to afatinib sensitivity is novel. Afatinib deserves further investigation in molecularly selected UC.

Source: Journal of Clinical Oncology - June 7, 2016 Category: Cancer & Oncology Authors: Choudhury, Campanile, Antic, Yap, Fitzpatrick, Wade, Karrison, Stadler, Nakamura, ODonnell Tags: Clinical Trials, Translational Oncology, Genitourinary, Cancer Biomarkers Urologic Oncology Source Type: research